182287-51-0

Basic information

• Product Name: 2-N-Boc-Amino-3-(4-tetrahydropyranyl)propionic acid
• Synonyms: [(TERT-BUTOXYCARBONYL)AMINO](TETRAHYDRO-2H-PYRAN-4-YL)ACETIC ACID;2-N-(TERT-BUTOXYCARBONYL)-AMINO-3-(4-TETRAHYDROPYRANYL)PROPIONIC ACID;2-N-BOC-AMINO-3-(4-TETRAHYDROPYRANYL)PROPIONIC ACID;2-TERT-BUTOXYCARBONYLAMINO-3-(TETRAHYDRO-PYRAN-4-YL)-PROPIONIC ACID;2-N-BOC-AMINO-3-(4-TETRAHYDROPYRANYL) PROPIONIC ACID 95%;2-N-BOC-Amino-3-(4-tetrahydropyranyl)propionic acid,95%;2-Boc-3-(tetrahydropyran-4-yl)-DL-alanine;N-{[(2-Methyl-2-propanyl)oxy]carbonyl}-3-(tetrahydro-2H-pyran-4-yl)alanine
• CAS NO: 182287-51-0
• Molecular Formula: C₁₃H₂₃NO₅
• Molecular Weight: 273.33
• EINECS: 200-456-8
• Mol File: 182287-51-0.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 416.35°C (rough estimate)
• Flash Point: 216.7 °C
• Appearance: White to off-white/Chunks
• Density: 1.1321 (rough estimate)
• Vapor Pressure: 8.92E-09mmHg at 25°C
• Refractive Index: 1.4800 (estimate)
• CAS DataBase Reference: 2-N-Boc-Amino-3-(4-tetrahydropyranyl)propionic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-N-Boc-Amino-3-(4-tetrahydropyranyl)propionic acid(182287-51-0)
• EPA Substance Registry System: 2-N-Boc-Amino-3-(4-tetrahydropyranyl)propionic acid(182287-51-0)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 37/39-26
• Hazardous Substances Data: 182287-51-0(Hazardous Substances Data)

Usage

Chemical Properties

white to off-white chunks

InChI:InChI=1/C13H23NO5/c1-13(2,3)19-12(17)14-10(11(15)16)8-9-4-6-18-7-5-9/h9-10H,4-8H2,1-3H3,(H,14,17)(H,15,16)/p-1/t10-/m0/s1

Upstream product

• 1620300-12-0 methyl (Z)-2-((tert-butoxycarbonyl)amino)-3-(tetrahydro-2H-pyran-4-yl)acrylate 
• 50675-18-8 3,4,5,6-tetrahydro-2H-pyran-4-carbaldehyde 
• 121056-95-9 trimethyl 2-(tert-butoxycarbonylamino)phosphonoacetate 

Relevant articles and documents

ALIPHATIC PROLINAMIDE DERIVATIVES

This invention is directed to novel aliphatic prolinamide derivatives of Formula I, and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye. These diseases include dry-AMD, wet-AMD, geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells. The invention disclosed herein is further directed to methods of prevention, slowing the progress of, and treatment of dry-AMD, wet-AMD, and geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells, comprising: administration of a therapeutically effective amount of compound of the invention. The compounds of the invention are inhibitors of HTRAl. Thus, the compounds of the invention are useful in the prevention and treatment of a wide range of diseases mediated (in whole or in part) by HTRAl. The compounds of the invention are also useful for inhibiting HTRAl protease activity in an eye or locus of an arthritis or related condition.